Europe
Galapagos NV announces topline interim results of Part 1 of the FALCON trial in cystic fibrosis (CF).
CALIBR is a division of the Scripps Research, a California non-profit corporation, dedicated to finding new treatments addressing unmet medical needs;
One of the new shareholders is an investment fund
myPTM Allows Patients to Personalize Their Treatment by Delivering On-Demand Boluses, or Drug Doses, Within Therapeutic Limits Set by Their Physician
Cash and cash equivalents of €219.9 million at September 30, 2018
Appointment to strengthen Zelluna’s financial and operational capabilities
Team from the University of Natural Resources and Life Sciences, Vienna, identifies conditions for inactivating Listeria while maintaining product quality during the processing of whey proteins
Combioxin SA announced an Oral Presentation highlighting successful first-in-human clinical results with CAL02 in severe pneumonia patients in ICU, at the ESICM’s annual congress, LIVES 2018, in Paris today.
Awarded a grant for vaccine development by the Bill & Melinda Gates Foundation
Seventure Partners, a specialist investor in the microbiome, commits new funding fromHealth for Life Capital™ and strengthens Microbiotica’s Board with microbiome sector expertise and know-how
PRESS RELEASES